(240 days)
Not Found
No
The description focuses on the mechanical function of a biopsy needle and does not mention any computational or analytical capabilities that would suggest AI/ML.
No.
The device is used for obtaining biopsy samples for diagnostic purposes, not for treating a disease or condition. While the information from the biopsy may lead to a therapeutic intervention, the device itself is not therapeutic.
Yes
The Biopsy Needle is used to obtain tissue samples for "histologic examination," which is a diagnostic process to analyze tissues for abnormalities. The intended use states it helps determine the "extent of histologic abnormality" and is used when the "sampled abnormality is not histologically benign." These all point to its role in diagnosing diseases or conditions.
No
The device description explicitly states it is a "Biopsy Needle" used to "remove, by cutting, a specimen of tissue". This is a physical, invasive medical device, not a software-only device. The performance studies also focus on physical characteristics and testing of the needle itself.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are medical devices used to examine specimens taken from the human body (like blood, urine, or tissue) to provide information about a person's health. This testing is performed outside of the body.
- Device Function: The Biopsy Needle is used to obtain a tissue sample from the body. It is a tool for collecting the specimen, not for performing the diagnostic test on the specimen itself.
- Intended Use: The intended use clearly states it's for "obtaining core biopsy samples" and "provide breast tissue sampling." This is a sample collection function.
- Device Description: The description reinforces that it's used to "remove, by cutting, a specimen of tissue."
While the tissue sample obtained by the biopsy needle will likely be used for in vitro diagnostic testing (histologic examination), the needle itself is the instrument for collection, not the diagnostic test.
N/A
Intended Use / Indications for Use
The Biopsy Needle is intended for use in obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses. Not intended for use in bone.
The Biopsy Needle is also indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities. It is designed to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.
The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality (e.g., malignancy). When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
Product codes
KNW
Device Description
The Biopsy Needle are used to remove, by cutting, a specimen of tissue for microscopic evaluation. The organs in which the device may be used include but are not limited to breast, kidney, liver, prostate, spleen and lymph nodes plus various soft tissue masses. As the device is single use device, which is individually packaged sterile devices. In the package, there is a whole device with the structure shown in the picture above without any accessories. The packaging is compatible with the product's EO sterilization method. The sterilization validation confirms the packaging is qualified bacterial film to maintain the sterilization condition of the device.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses, breast
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
The subject devices in their packaging were subjected to accelerated aging to simulate a 5 year shelf life (Treatment: 60°C, 162 days,
§ 876.1075 Gastroenterology-urology biopsy instrument.
(a)
Identification. A gastroenterology-urology biopsy instrument is a device used to remove, by cutting or aspiration, a specimen of tissue for microscopic examination. This generic type of device includes the biopsy punch, gastrointestinal mechanical biopsy instrument, suction biopsy instrument, gastro-urology biopsy needle and needle set, and nonelectric biopsy forceps. This section does not apply to biopsy instruments that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification. (1) Class II (performance standards).(2) Class I for the biopsy forceps cover and the non-electric biopsy forceps. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
0
January 29, 2020
Ushare Medical Inc. % Raymond Luo Technical Manager Shanghai Sungo Management Consulting Co., Ltd. 13th F, 1500# Century Avenue Shanghai, China 200122
Re: K191472
Trade/Device Name: Biopsy Needle Regulation Number: 21 CFR 876.1075 Regulation Name: Gastroenterology-Urology-Urology Biopsy Instrument Regulatory Class: Class II Product Code: KNW Dated: December 2, 2019 Received: December 2, 2019
Dear Raymond Luo:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Long Chen, Ph.D. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K191472
Device Name Biospy Needle
Indications for Use (Describe)
The Biopsy Needle is intended for use in obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses. Not intended for use in bone.
The Biopsy Needle is also indicated to provide breast tissue sampling of breast abnormalities. It is designed to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.
The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality (e.g., malignancy). When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
| Type of Use (Select one or both, as applicable) | Prescription Use (Part 21 CFR 801 Subpart D) Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of
information unless it displays a currently valid OMB number."
3
510(K) Summary
Date of preparation: 2020-1-28
1. Applicant:
Company Name: Ushare Medical Inc. Company Address: 445 An Ji Zhong Road, San Zao Town, Zhuhai, Guangdong, P. R. China Contact Person Name: Amy Wang (Ms.) Title: Quality Manager Tel: 0086-756-7516888 Mail: qm(@usharemedical.com
Official Contact Person Information
Company Name: Shanghai Sungo Management Consulting Company Limited Contact Person Name: Raymond Luo (Mr.) Title: Technical Manager Tel: 0086-21-68828050 Mail: fda.sungo@gmail.com
2. Current Device:
The proprietary name of the new device: Biopsy Needle The generic name of the device: Instrument, Biopsy Classification regulation: 21 CFR 876.1075 Classification: Class II. Regulation Medical Specialty: Gastroenterology/Urology Product code: KNW
3. Predicate device:
K number: K141552 Company: CareFusion Address: 75 North Fairway Drive, Vernon Hills, IL 60061 USA Predicate Device: Achieve Programmable Automatic Biopsy Systems
4. Intended use of the device:
The Biopsy Needle is intended for use in obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses. Not intended for use in bone.
The Biopsy Needle is also indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities. It is designed to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality.
The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality (e.g., malignancy). When the sampled abnormality is not histologically
4
benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures.
5. Device Description:
The sketch of the product structure and the dimension is shown in the figure below.
The Biopsy Needle are used to remove, by cutting, a specimen of tissue for microscopic evaluation. The organs in which the device may be used include but are not limited to breast, kidney, liver, prostate, spleen and lymph nodes plus various soft tissue masses. As the device is single use device, which is individually packaged sterile devices. In the package, there is a whole device with the structure shown in the picture above without any accessories. The packaging is compatible with the product's EO sterilization method. The sterilization validation confirms the packaging is qualified bacterial film to maintain the sterilization condition of the device.
6. Current Device and Predicate Device Technical Characteristics
The proposed Biopsy Needle is substantially equivalent to the predicate Achieve Programmable Automatic Biopsy Systems with regards to claims, design, technology, and intended use. Refer to the Side by Side Comparison Table below.
6.1 Device Format
The subject disposable biopsy devices share format as the predicate devices for sterile, single use, and EO compatible packaging. Results from device testing indicate that subject devices are non-pyrogenic.
5
| Predicate | |
|---|---|
| Device | |
| A Fully Automatic | |
| D-Stylet Only | |
| ACHIEVE™ | |
| Programmable Automatic Biopsy System |
6.2 Technical Characteristics
| Device | Current Device | Predicate Device |
|---|---|---|
| Manufacturer | Ushare Medical Inc. K191472 | CareFusion K141552 |
| Model Name | MBN Series Biopsy Needle | Achieve Programmable Automatic Biopsy Systems |
| Classification | Class II Device, KNW | Class II Device, KNW, |
| Intend use | The Biopsy Needle is intended for use in obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses. Not intended for use in bone. | |
| The Biopsy Needle is also indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities. It is designed to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality. | ||
| The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality (e.g., malignancy). When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures. | The Achieve Programmable Automatic Biopsy Systems is intended for use in obtaining core biopsy samples from soft tissue such as kidney, liver, prostrate, spleen, lymph nodes, and various soft tissue masses. Not intended for use in bone. | |
| The Achieve Programmable Automatic Biopsy Systems is also indicated to provide breast tissue samples for diagnostic sampling of breast abnormalities. It is designed to provide breast tissue for histologic examination with partial or complete removal of the imaged abnormality. | ||
| The extent of histologic abnormality cannot be reliably determined from its mammographic appearance. Therefore, the extent of removal of the imaged evidence of an abnormality does not predict the extent of removal of a histologic abnormality (e.g., malignancy). When the sampled abnormality is not histologically benign, it is essential that the tissue margins be examined for completeness of removal using standard surgical procedures. | ||
| Designated | ||
| metric size | 14G, 16G, 18G, 20G | 12G, 14G, 16G, 18G, 20G |
| Length L(mm) | 100mm, 150mm, 200mm | 60mm, 90mm, 110mm, 150mm, 200mm, 250mm |
| Slot size | 10mm, 15mm, 20mm | 20mm |
| Cannula and | ||
| Stylet | The cannula is designed with an outer cutting cannula having a sharpened tip and an inner | The cannula is designed with an outer cutting cannula having a sharpened tip and an inner |
6
| stylet with sample slot. | stylet with sample slot. | |
|---|---|---|
| Needle | ||
| Advancement | ||
| and Tissue | ||
| Access | Biopsy Needle with guillotine coring and the | |
| predicate device with guillotine coring provide | ||
| the clinician with the same single or two-stage | ||
| (sequential) automatic advancement for fixed | ||
| sample length for tissue penetration and cutting. | Same as current device | |
| Mechanism of | ||
| Action | single-hand automatic activation | Same as current device |
| Usability and | ||
| Convenience | Provide design features that facilitate clinician | |
| use during biopsies: cannula centimeter marks, | ||
| echogenic radiographic visibility, color coded | ||
| needle hubs, and adjustable depth stops. | Same as current device | |
| Standard | Biocompatibility: ISO10993-1 (ISO10993-4, | |
| ISO10993-5, ISO10993-10, ISO10993-11) | ||
| Sterilization: ISO11135, ISO11138, ASTM | ||
| F1980, ISO11737-1, ISO10993-7, ISO11607 | ||
| Performance: ISO9626 | Biocompatibility: ISO10993-1 | |
| Sterilization: ISO11135, ISO11138, ASTM | ||
| F1980, ISO11737-1, ISO10993-7, ISO11607 | ||
| Performance: ISO9626 | ||
| Comparison | ||
| testing | Pressing parts, Pressing parts firing force, | |
| Cannula firing force, Safety switch, Sampling | ||
| switch, Scale marks firmness, Total heavy metal | ||
| content, Scale mark identification, Sampling | ||
| structure, Sampling method, Penetration force, | ||
| Biopsy Sample Testing, Ultrasound Visibility | ||
| Testing | Pressing parts, Pressing parts firing force, | |
| Cannula firing force, Safety switch, Sampling | ||
| switch, Scale marks firmness, Total heavy metal | ||
| content, Scale mark identification, Sampling | ||
| structure, Sampling method, Penetration force, | ||
| Biopsy Sample Testing, Ultrasound Visibility | ||
| Testing |
The technological characteristics of the subject device are identical to those of predicate device. The subject device has the same basic design as the predicate device. The comparison between the subject and predicate devices is based on the following:
- Same intended use
- Same indications for use
- · Similar material types that meet ISO 10993 biocompatibility requirements
- · Same sterilization methods
- · Same fundamental technology/principal of operation/user interface
The disposable biopsy device needle designs display minor differences between the subject device and the predicate devices for gauge and needle length. The Max and Min size of the current device were covered by the predicate device. There is no significant risk raised by the difference.
| Characteristic | Standard | Content |
|---|---|---|
| Biocompatibility | AAMI/ANSI/ISO | |
| 10993-1 | Biological evaluation of Medical Devices Part 1: Evaluation | |
| and Testing | ||
| Biocompatibility | ISO 10993-4 | Biological evaluation of medical devices--Part 4: Selection of tests for |
7. Performance Testing
7.1 Biocompatibility and Sterility
7
| interactions with blood | ||
|---|---|---|
| Biocompatibility | ISO 10993-5 | Biological evaluation of medical devices - Part 5: Tests for in vitro |
| cytotoxicity | ||
| Biocompatibility | ISO 10993-10 | Biological evaluation of medical devices - Part 10: Tests for irritation and skin |
| sensitization | ||
| Biocompatibility | ISO 10993-11 | Biological evaluation of medical devices - Part 11: Tests for systemic toxicity |
| Sterilization | ISO11135 | Medical Device, Validation and Routine Control of Ethylene Oxide |
| Sterilization | ||
| Residuals | ISO10993-7 | Biological evaluation of Medical Devices Part 7: Ethylene |
| Oxide Sterilization Residuals | ||
| Sterilization | ANSI/AAMI/ISO | |
| 11607 | Packaging for Terminally Sterilized Medical Devices | |
| Sterilization | ASTM F1980-07 | Accelerated Aging of Sterile Barrier Systems |
7.2 Device Shelf-life
The subject devices in their packaging were subjected to accelerated aging to simulate a 5 year shelf life (Treatment: 60°C, 162 days,